OncoMatch/Clinical Trials/NCT06979596
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Is NCT06979596 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments for malignant neoplasm.
Treatment: Opevesostat · Fludrocortisone/ Fludrocortisone acetate · Dexamethasone/Dexamethasone acetate · Rescue Medications · Fulvestrant · Exemestane · Megestrol acetate/Medroxyprogesterone acetate · Tamoxifen · Letrozole — Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Tumor Agnostic
Breast Carcinoma
Ovarian Cancer
Endometrial Cancer
Prior therapy
Must have received: endocrine-based therapy — metastatic HR+/HER2- breast cancer
Has experienced disease progression on or after at least 1 prior endocrine-based therapy in the metastatic setting and received either, 1 line of an approved protocol-specified combination endocrine-based therapy, or 2 or more lines of protocol-specified endocrine-based therapy in the metastatic setting
Must have received: platinum-based doublet chemotherapy — third-line (3L) ovarian cancer
Has received between 4 to 8 cycles of platinum-based doublet chemotherapy in third-line (3L) setting for ovarian cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Womens Cancer Care ( Site 0037) · Anchorage, Alaska
- Mount Sinai Cancer Center ( Site 0009) · Miami Beach, Florida
- TRIALS 365 ( Site 0022) · Shreveport, Louisiana
- Mary Lanning Healthcare ( Site 0019) · Hastings, Nebraska
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0021) · Hackensack, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06979596 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received endocrine-based therapy and platinum-based doublet chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages